In NASH Race, Bad News For Conatus, Good News For Genfit In PBC

 
• By Joseph Haas

Conatus’ emricasan fails to meet the primary endpoint for portal hypertension in NASH patients with cirrhosis, but firm stresses promising subgroup data. Genfit hits Phase II primary endpoint in PBC with elafibranor, which is also in Phase III for NASH.

female scientist working with microscope

More from Alimentary/Metabolic

More from Therapy Areas